Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Colorectal Neoplasms 91Stomach Neoplasms 44Pancreatic Neoplasms 37Rectal Neoplasms 29Colonic Neoplasms 23Neoplasms 22Esophageal Neoplasms 21Squamous Cell Carcinoma of Head and Neck 20Neoplasm Metastasis 18Cholangiocarcinoma 16Adenocarcinoma Of Esophagus 16Biliary Tract Neoplasms 13Parkinson Disease 4, Autosomal Dominant Lewy Body 12Head and Neck Neoplasms 12Esophageal Squamous Cell Carcinoma 12Carcinoma, Non-Small-Cell Lung 12Adenocarcinoma 12Urinary Bladder Neoplasms 11Ovarian Neoplasms 9Gastrointestinal Neoplasms 9Carcinoma, Hepatocellular 7Endometrial Neoplasms 6Breast Neoplasms 6Gallbladder Neoplasms 5Advanced Solid Tumors 5Uterine Cervical Neoplasms 4Peritoneal Neoplasms 4Lung Neoplasms 4Carcinoma 4Appendiceal Neoplasms 4

Interventions

Injections 13pembrolizumab 10tislelizumab 9toripalimab 6atezolizumab 4Nivolumab 4Carboplatin 3trastuzumab deruxtecan 2olaparib 2lenvatinib 2Pemetrexed 2Paclitaxel 2Oxaliplatin 2Gemcitabine 2Fluorouracil 2Docetaxel 2Cyclophosphamide 2Cisplatin 2Cetuximab 2Bevacizumab 2zimberelimab 1talazoparib 1spartalizumab 1sotorasib 1serabelisib 1penpulimab 1niraparib 1nedaplatin 1mirdametinib 1fludarabine phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Advanced Solid Tumor × Fluorouracil × 1 year × Clear all
NCT06509906 2025-12-18

M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

EMD Serono

Phase 1 Terminated
3 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT07256782 2025-12-01

A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Recruiting
444 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡